PubMed · 41891155
Oxeiptosis - potential in cancer treatment?
Abstract
Oxeiptosis is a reactive oxygen species (ROS)-dependent form of programmed cell death that plays a key role in cellular homeostasis and holds promise as a cancer therapy. This review explores its molecular mechanisms, emphasizing the KEAP1-PGAM5-AIFM1 signalling pathway and its reliance on ROS accumulation. Compared to other cell death pathways, oxeiptosis offers a distinct approach, especially for targeting cancer cells resistant to conventional therapies. The review evaluates emerging inducers, both synthetic and natural, that selectively trigger oxeiptosis in cancer cells. It also examines the potential synergy between oxeiptosis and ROS-generating chemotherapies, particularly in the oxidative tumour microenvironment. However, challenges remain, including identifying tumour-specific inducers, overcoming cancer cell resistance to oxidative stress and reducing off-target effects. The review concludes by highlighting the need for targeted delivery strategies and rigorous preclinical studies to translate oxeiptosis into effective cancer treatments. Overall, it underscores oxeiptosis as a promising avenue to address drug resistance and improve therapeutic outcomes in oncology.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Mateusz Kciuk, Katarzyna Wanke, Żaneta Kałuzińska-Kołat, Renata Kontek. 2026-03-27. Oxeiptosis - potential in cancer treatment?. https://doi.org/10.1017/erm.2026.10045
Cite the original work for its findings. Save a collection to share your selection of sources.